Novel Treatment Strategies in the Management of Ovarian Cancer: A Closer Look at the Role of PARP Inhibitors

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 30, 2018 to June 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from AstraZeneca

According to the National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER) there will be an estimated 22,440 new cases of ovarian cancer this year in the United States. The five-year survival rate is approximately 45%, leading to an estimated 14,080 deaths in the US. Ovarian cancer is usually found in stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen. This is due in large part to a lack of symptoms during the earlier stages. The treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in ovarian cancer include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.

Upon Completion of this activity, participants will be able to:

  • Analyze recent safety, efficacy and tolerability data on PARP inhibitors in the management of ovarian cancer

  • Describe factors that impact treatment decision-making throughout the course of advanced ovarian cancer

  • Assess the role of germline and somatic BRCA testing and other biomarkers of genomic instability

  • Evaluate the role of PARP inhibitors as maintenance therapy for relapsed platinum-sensitive disease

  • Identify adverse events associated with PARP inhibitors, and select appropriate strategies to help ensure patient treatment adherence and optimum quality of life

  • Apply methods to enable optimal cost management of PARP inhibitors to be realized by multiple ovarian cancer stakeholders including managed care organizations

Faculty: MDon S Dizon, MD, FACP, FASCO
Director, Women's Cancers
Lifespan Cancer Institute
Director, Medical Oncology
Rhode Island Hospital
Associate Professor of Medicine
The Warren Alpert Medical School of Brown University


Dr. Dizon has no relevant financial relationships to disclose. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue